/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

C

Claudia Proto

Fondazione IRCCS Istituto Nazionale dei Tumori(IT)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

291

Papers

4.0K

Citations

31

h-index

62

i10-index

Claudia Proto is an academic researcher from Fondazione IRCCS Istituto Nazionale dei Tumori. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Lung Cancer Treatments and Mutations & Lung Cancer Research Studies. The author has an h-index of 31, co-authored 248 publications.

ORCID: 0000-0003-0287-9787

Research Topics

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Lung Cancer Research Studies Immunotherapy and Immune Responses Cancer Genomics and Diagnostics

Papers by this author

works

Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors

2019 · ESMO Open · 203 citations

https://doi.org/10.1136/esmoopen-2018-000457

Giovanni Fucà Giulia Galli M. Poggi Giuseppe Lo Russo

Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program

2021 · European Journal of Cancer · 57 citations

https://doi.org/10.1016/j.ejca.2021.02.038

Arsela Prelaj Achille Bottiglieri Claudia Proto Giuseppe Lo Russo

Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules

2016 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · 16 citations

https://doi.org/10.1007/s00428-016-1931-z

Giuseppe Pelosi Alessio Pellegrinelli Alessandra Fabbri Elena Tamborini

184P Bone-targeted agents (BTA) improve survival in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD-(L)-1 inhibitors (ICIs)

2021 · Journal of Thoracic Oncology · 5 citations

https://doi.org/10.1016/s1556-0864(21)02026-8

Sara Manglaviti Giulia Galli Marta Bini Alice Labianca

High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors

2023 · Lung Cancer · 3 citations

https://doi.org/10.1016/j.lungcan.2023.107417

Sara Manglaviti Marta Bini Giulia Apollonio Ernesto Zecca

Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs

2024 · Tumori Journal · 3 citations

https://doi.org/10.1177/03008916241246659

Rita Leporati Daniela Miliziano Teresa Beninato Laura Mazzeo

Research topics

topics

Cancer Immunotherapy and Biomarkers

Lung Cancer Treatments and Mutations

Lung Cancer Research Studies

Immunotherapy and Immune Responses

Cancer Genomics and Diagnostics

Chat about Author

Papers

Chat

Click to start Chat